CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms
about
Heparan sulfate proteoglycans in the control of B cell development and the pathogenesis of multiple myelomaDevelopment of Novel Immunotherapies for Multiple MyelomaFibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients.Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic DeviceAssessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.Bone marrow plasma cell assessment before peripheral blood stem cell mobilization in patients with multiple myeloma undergoing autologous stem cell transplantation.CD138 (Syndecan-1) in thymic tumors: correlation with various World Health Organization types and clinical outcome.Autoimmune chronic pancreatitis with IgG4-related pancreatic pseudocyst in a patient undergoing total pancreatectomy followed by autologous islet transplantation: a case reportDiagnostic and prognostic value of soluble syndecan-1 in pleural malignancies.Synthesis of syndecan-1 by skeletal muscle cells is an early response to infection with Trichinella spiralis but is not essential for nurse cell development.Hypergammaglobulinemia in an SIV-infected rhesus macaque with a B-cell neoplasm with plasma cell differentiation.Non-invasive bioluminescence imaging to monitor the immunological control of a plasmablastic lymphoma-like B cell neoplasia after hematopoietic cell transplantation.Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies.CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.Leukocyte Populations in Human Preterm and Term Breast Milk Identified by Multicolour Flow Cytometry.High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myelomamicroRNA-145 promotes differentiation in human urothelial carcinoma through down-regulation of syndecan-1.The proteoglycan repertoire of lymphoid cellsOcular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical TrialsMorphometric analysis of inflammation in bronchial biopsies following exposure to inhaled diesel exhaust and allergen challenge in atopic subjects.Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma.Characterization of c-Maf transcription factor in normal and neoplastic hematolymphoid tissue and its relevance in plasma cell neoplasiaVirally-induced upregulation of heparan sulfate on B cells via the action of type I IFN.Solitary plasmacytoma of the mandible - a rare entity.CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.Cytology of plasma cell rich effusion in cases of plasma cell neoplasm.Heparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Follicular B cells in thyroids of mice with spontaneous autoimmune thyroiditis contribute to disease pathogenesis and are targets of anti-CD20 antibody therapy.The utility of immunohistochemistry for the identification of hematopoietic and lymphoid cells in normal tissues and interpretation of proliferative and inflammatory lesions of mice and rats.Plasmacytoid urothelial carcinoma--diagnostic challenge in cytology.The role of syndecan-1 in cellular signaling and its effects on heparan sulfate biosynthesis in mesenchymal tumorsGoing viral: chimeric antigen receptor T-cell therapy for hematological malignancies.Activation of the B cell antigen receptor triggers reactivation of latent Kaposi's sarcoma-associated herpesvirus in B cells.Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.Flow cytometry assessment of in vitro generated CD138+ human plasma cells.New monoclonal antibodies on the horizon in multiple myelomaEvolving Approaches in the Identification of Allograft-reactive T and B Cells in Mice and Humans.Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
P2860
Q27001749-3150E34C-DFFA-4DB1-ABF0-CF2B56495288Q28066890-76414CF2-B396-4CB8-B2E6-B924B0260F3BQ30449589-BD5A4816-2472-4E1A-9876-30C79AA29BB0Q30843897-9877BBE7-18F5-4681-9F12-B817FADE1468Q33294938-C715595C-5B74-446F-B4A3-9CA6099F7EE5Q33660396-9C62D11B-3D40-4D90-AB1D-3AE4D81F663CQ33719174-B0F33789-986B-4BD3-8F4E-AA36B335A094Q33875349-44316948-A322-42CA-950F-9CF1CDB456EAQ34039967-A9DBFD80-8E18-4874-8898-6C1F89005879Q34491664-101E328D-754C-426D-9F2B-C4BBCF375666Q34993404-DC373C1F-765B-42C7-9FC6-53A7519746B7Q35069537-D2A271CB-B4F4-4C8B-BD9E-85548A76F1AAQ35071821-147929BB-F940-4782-B4EC-CD532017C0EDQ35610286-FF5E79E8-D645-4932-B8DA-EFF987AFAF67Q35750371-A44363E0-1464-4DB9-BDAA-1AD62849E07CQ35789280-B23F4679-A88F-49B0-9FE5-255D7E0F9881Q35826468-E22541BC-D952-455C-8F28-781B44B4F859Q36208202-D4DF2518-E1F7-4A22-A6D6-298382CD6E90Q36366709-C4A57A59-7FDC-42E7-9695-885DDCF32F70Q36457620-0001ABD5-B177-43F6-8694-0665870459E4Q36527905-AEC4A4A5-11E0-4912-926F-045195B6B1CBQ36841985-8E3C134A-AFE7-49EC-9E16-7DB4C1088F2CQ36916401-B9D87FCB-1832-4615-B473-614565FBB71DQ37162365-7E5A8ECD-5B81-4910-917F-3689B3C7A84BQ37176556-1AEE2BC1-32D0-49DE-98AD-702A1548E3F7Q37199751-FBB5CAF3-32F2-49AA-B0AE-1B1712BE94A2Q37499263-AFC1F33A-949A-414A-A05D-C28470D4E2B8Q37512037-FAE2E68C-3427-4C89-B7A2-3E2DAC0756A3Q37995585-D93AF66E-BBAA-46A3-89AB-F3168CB25FF1Q38006912-13C72582-178D-484D-999F-5E2F95B8DFAEQ38176008-534D7F81-A1BD-43E8-8FAE-34529D2D3866Q38289029-BEB09BBB-0060-423E-90D4-31D3D956A8B6Q38315444-EAD4F788-6D81-4BBE-A7DA-5BE4F69C023BQ38760595-11876170-8FD8-4484-8410-6260DBE323BCQ38764944-273742BD-A02B-4E6F-95DF-4CF1D04E5154Q38868904-EB4A8967-0BEA-4A41-B5A0-77B30DCB0C7AQ39009554-F4A440CE-3CA6-4310-83F0-AE22B478E065Q39137696-F7BC7D96-94B4-4663-86D9-9E7AE2B9D49AQ39366464-36A7BDE2-B7D7-4C33-B184-4D10046C94C6Q39799509-95468E24-9EC1-4EDC-A4FC-B0B6751E6AC7
P2860
CD138 (syndecan-1), a plasma cell marker immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms
description
2004 nî lūn-bûn
@nan
2004 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@ast
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@en
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@nl
type
label
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@ast
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@en
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@nl
prefLabel
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@ast
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@en
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@nl
P2093
P3181
P1476
CD138 (syndecan-1), a plasma c ...... and nonhematopoietic neoplasms
@en
P2093
Fionnuala P O'Connell
Geraldine S Pinkus
Jack L Pinkus
P304
P3181
P356
10.1309/617D-WB5G-NFWX-HW4L
10.1309/617DWB5GNFWXHW4L
P407
P577
2004-02-01T00:00:00Z